Drugmakers Tackle Biosimilars Oversight At FTC Forum

Law360, New York (February 4, 2014, 5:18 PM EST) -- Amgen Inc., Sandoz Inc. and other drugmakers locked horns Tuesday at a Federal Trade Commission forum examining state-level restrictions on pharmacy substitution of biosimilars and whether the copycat medicines should have distinct names, marking one of the highest-profile debates yet over the nascent field’s future.

The wrangling focused partly on legislation that’s been floated in at least 18 states — and enacted in at least four states — to regulate biosimilar access. The most controversial provisions require physician notification if a biosimilar is dispensed in place...
To view the full article, register now.